0001209191-23-021412.txt : 20230328
0001209191-23-021412.hdr.sgml : 20230328
20230328164554
ACCESSION NUMBER: 0001209191-23-021412
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230324
FILED AS OF DATE: 20230328
DATE AS OF CHANGE: 20230328
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Feingold Jay
CENTRAL INDEX KEY: 0001885838
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40881
FILM NUMBER: 23770206
MAIL ADDRESS:
STREET 1: C/O PYXIS ONCOLOGY, INC.
STREET 2: 35 CAMBRIDGEPARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pyxis Oncology, Inc.
CENTRAL INDEX KEY: 0001782223
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 831160910
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 CAMBRIDGE PARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
BUSINESS PHONE: (617) 221-9059
MAIL ADDRESS:
STREET 1: 35 CAMBRIDGE PARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-03-24
0
0001782223
Pyxis Oncology, Inc.
PYXS
0001885838
Feingold Jay
C/O PYXIS ONCOLOGY, INC.
150 CAMBRIDGEPARK DRIVE
CAMBRIDGE
MA
02140
0
1
0
0
Chief Medical Officer
0
Common Stock
2023-03-24
4
A
0
209803
0.00
A
730345
D
Stock Option (Right to buy)
8.71
2023-03-24
4
D
0
157257
D
2031-09-12
Common Stock
157257
0
D
Stock Option (Right to buy)
8.71
2023-03-24
4
D
0
17517
D
2031-09-14
Common Stock
17517
0
D
Stock Option (Right to buy)
2.21
2023-03-24
4
A
0
157257
A
2031-09-12
Common Stock
157257
157257
D
Stock Option (Right to buy)
2.21
2023-03-24
4
A
0
17517
A
2031-09-14
Common Stock
17517
17517
D
Represents restricted stock units that vest 25% on March 24, 2024, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.
These stock options vested 25% on the first anniversary of the September 13, 2021 grant date, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
These stock options vested 25% on the first anniversary of the closing of the Issuer's initial public offering, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
/s/ Pamela Connealy, Attorney-in-Fact for Jay Feingold
2023-03-28